| 英文名稱 | Methyl protodioscin |
|---|---|
| 中文名稱 | 甲基原薯蕷皂苷/甲基原薯蕷皂甙 |
| CAS號 | 54522-52-0 |
| 分子式 | C52H86O22 |
| 分子量 | 1063.23 |
| 外觀 | 白色粉末 |
| 熔點 | 175-177 °C |
| 酸度系數pKa | 12+-.0.70 | Condition: Most Acidic Temp: 25 °C |
| 英文名稱 | Methyl protodioscin |
|---|---|
| 中文名稱 | 甲基原薯蕷皂苷/甲基原薯蕷皂甙 |
| CAS號 | 54522-52-0 |
| 分子式 | C52H86O22 |
| 分子量 | 1063.23 |
| 外觀 | 白色粉末 |
| 熔點 | 175-177 °C |
| 酸度系數pKa | 12+-.0.70 | Condition: Most Acidic Temp: 25 °C |
WKQ-0000300
中文名稱：甲基原薯蕷皂苷
中文別名：甲基原薯蕷皂甙
英文名稱：Methyl protodioscin
英文別名：(3β,22α,25R)-26-(β-D-Glucopyranosyloxy)-22-methoxyfurost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[6-deoxy-α-L-mannopyranosyl-(1→4)]-β-D-glucopyranoside;22-Methoxylprotodioscin;22-O-Methylprotodioscin;3β,26-Dihydroxy-22α-methoxyfurost-5-ene 3-O-β-chacotrioside 26-O-β-D-glucopyranoside;Methylprotodioscin;NSC 698790;Smilax saponin B;
分子式：C52H86O22
分子量：1063.23
CAS號：54522-52-0
純度：HPLC≥98%
熔點：175-177 °C
密度：1.43±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
酸系度數：12+-.0.70 | Condition: Most Acidic Temp: 25 °C
儲存條件：-20℃，干燥、避光、密封
規格：5mg10mg20mg50mg100mg500mg1g2g等應客戶需求包裝
供應單位：四川省維克奇生物科技有限公司
供應電話：028-81700200/4008005713
四川省維克奇生物科技有限公司生產中藥類標準品和天然植物有效單體，主打中藥對照品/標準品/天然植物有效單體，化學合成，抗生素三大板塊。公司推出丹參系列、龍膽系列、蟲草系列等，敬請關注！ 新批次有現貨，歡迎咨詢。
| Drug interaction study of natural steroids from herbs specifically toward human UDP-glucuronosyltransferase (UGT) 1A4 and their quantitative structure activity relationship (QSAR) analysis for prediction | ||
| 來源：SCI：PHARMACOLOGICAL RESEARCH | 作者：Min Xu | 備注：影響因子：4.816 |
| 引用描述 | ||
hecogenin (1), diosgenin (2), ruscogenin (3), gitogenin (4), tigogenin (5), solasodine (6), (24S,25S)-3β, 24-di-hydroxy-5α-spirostan (7), dracaenol C (8), 25(27)-dehydroruscogenin (9), (1β, 3β, 14α, 15α, 20R, 22S, 25R)-spirost-5-ene-tetrol (10), peimine (11), peiminine (12), peimisine (13), isoverticine (14), trillin (15), polyphyllin VI (16), polyphyllin VII (17), pallidifloside D (18), prosapogenin A (19), spongipregnoloside A (20), dioscin(21), solasonine (22), solamargine (23), gracillin (24), polyphyllin I(25), timosaponin BII (26), timosaponinA-III(27), ophiopogonin D (28), protobioside (29), (22S,25S)-26-O-β-d-glucopyranosyl-22,25-epoxyfurost-5-en-3β,26-diol-3-O-α-l-rha-mnopyranosyl(1 → 2)-β-d-gluc (30), pallidifloside E (31), parispseudoside (32), methylprotodioscin (33), protodioscin (34), pseudoprotodioscin (35), YS-IX (36), pallidifloside A (37), pallidifloside H (38), digoxin (39), bisdigoxigenin (40), 7β, 14α, 21-tri-hydroxy-diosgenin (41), 12β,14α,21-tri-hydroxy-diosgenin (42), and 11β,14α-di-hydroxyldiosgenin (43) were purchase from Sichuan weikeqi biotechnology company (Sichuan province, China). Pooled human liver microsomes (HLMs, 20 mg/mL) and pooled human primary hepatocytes were purchased from Rild Research Institute for LiverDiseases (Shanghai, China). | ||
| Pseudoprotodioscin inhibits SREBPs and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides | ||
| 來源：SCI：FITOTERAPIA | 作者：Yanan Gai | 備注：影響因子：2.431 |
| 引用描述 | ||
for the Control of Pharmaceutical and Biological Products (Beijing, China) (Fig. 1a). Dioscin (DC), pseudoprotodioscin (PPD) and methylprotodioscin (MP) were bought from Sichuan Weikeqi Biological Technology Co. Ltd. (Sichuan, China) (Fig. 1a). | ||
